Septerna (NASDAQ:SEPN) Shares Gap Up – Here’s Why

Septerna, Inc. (NASDAQ:SEPN) gapped up prior to trading on Wednesday . The stock had previously closed at $14.54, but opened at $15.34. Septerna shares last traded at $14.57, with a volume of 10,601 shares changing hands.

Analysts Set New Price Targets

Several brokerages have weighed in on SEPN. Wells Fargo & Company started coverage on Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 price objective for the company. TD Cowen began coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating on the stock. Cantor Fitzgerald assumed coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $50.00 price target for the company. Finally, JPMorgan Chase & Co. began coverage on Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price on the stock.

Septerna Stock Up 1.4 %

The business’s 50-day moving average is $20.93.

Institutional Investors Weigh In On Septerna

Institutional investors have recently modified their holdings of the business. SG Americas Securities LLC purchased a new position in Septerna in the 4th quarter worth about $185,000. Rhumbline Advisers bought a new position in shares of Septerna in the fourth quarter worth approximately $458,000. New York State Common Retirement Fund bought a new stake in shares of Septerna during the 4th quarter valued at $32,000. Bank of New York Mellon Corp purchased a new position in shares of Septerna during the 4th quarter valued at $872,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Septerna in the 4th quarter worth $3,197,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.